Zhengye Biotechnology Holding Ltd (ZYBT): Shareholders' Equity

Annual figures by period end, from SEC filings.

306.71M CNY
As of 2025-12-31
-4.9%
3-year compound annual growth
356.87M CNY2022-12-31: 356.87M CNY2023-12-31: 339.27M CNY2024-12-31: 352.54M CNY2025-12-31: 306.71M CNY306.71M CNY
2022-12-31 Shareholders' Equity (CNY) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31306.71M CNY-13.0%2026-04-28, Balance as of period end
2024-12-31352.54M CNY+3.9%2026-04-28, Balance as of period end
2023-12-31339.27M CNY-4.9%2026-04-28, Balance as of period end
2022-12-31356.87M CNYn/a2025-07-03, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Zhengye Biotechnology Holding Ltd (ZYBT)2025-12-31306.71M CNY-13.0%
Yatsen Holding Ltd (YSG)2025-12-313.00B CNY-1.7%

Compare ZYBT, YSG side by side · Screen every company in Pharmaceutical Preparations ↗